ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
 
Print Page
Email Article

Newcastle Group Implements New Diagnostic Tool for ME/CFS

  [ 1 vote ]   [ Post a Comment ]
www.ProHealth.com • February 28, 2013

previous article next article

Editor's Comment: The CDC, or “Fukuda,” case definition for CFS has been criticized for inaccuracy. The Canadian Case Definition, which is accurate, but lengthy, was revised in 2010 to make it more accessible to clinicians. The questionnaire referred to in this article is based on the revised Canadian Criteria. These, while comprehensive, contain an exclusion of “any active medical condition that may explain the presence of chronic fatigue.” Those who do not consider fatigue but post-exertional malaise as the primary symptom of ME/CFS find this phrase objectionable.

Press Release: Evaluating the DePaul Symptom Questionnaire in the ME Research UK cohort: extension study

Investigator: Prof. Julia Newton

Institution: Institute for Ageing and Health, The Medical School, Newcastle University, Newcastle upon Tyne, UK

Funding: Funding for this study has been provided by ME Research UK

Background and Aim

Since 2006, the group at Newcastle University has received several grants from ME Research UK. The largest of these (£130,000), awarded in conjunction with the John Richardson Research Group and the Irish ME Trust in 2007, was to investigate autonomic nervous system parameters along with muscle, liver and heart function in a large patient cohort. A series of novel scientific papers has emanated from this programme of work, and the researchers have reported that, compared with healthy people, many ME/CFS patients have a) impaired cardiac function, including reduced cardiac mass and blood pool volumes; b) dysfunction of the autonomic nervous system; c) fatigue that is directly related to the burden of autonomic nervous system symptoms; d) an abnormal heart rate response to standing; e) a lower blood pressure, and abnormal blood pressure regulation; and f) substantially slower recovery from standardised exercise of the skeletal muscles.). In the context of ME/CFS, these findings have had an important impact, most particularly in pointing up key areas of importance for diagnosis – a particularly useful outcome given the difficulties of diagnosis faced by patients and clinicians.

At present there are several case definitions for ME/CFS, however, but all are exclusionary and rely on collections of non-specific symptoms shared with other illnesses. For example, the most widely used case definition is the Fukuda (1994) criteria which uses polythetic criteria (i.e., patients are only required to have 4 out of a possible 8 symptoms), but 2 of these 8 symptoms (post-exertional malaise and memory/concentration problems) are thought to be an essential feature of the illness and the Fukuda criteria do not require that these symptoms be present among all patients.

Significant methodological problems could occur if investigators in different settings recruit samples with different percentages of these core symptoms. By contrast, the Canadian clinical case definition (2003) requires specific ME/CFS symptoms such as post-exertional malaise and memory/concentration problems to be present, but this case definition tends to be more complex to apply and has been used relatively rarely for diagnosis or research purposes compared with the more widely used Fukuda definition. Importantly, neither of these definitions has been formally operationalised.

Prof. Leonard Jason at DePaul University, Chicago has been in the forefront of research into the development and application of diagnostic criteria for ME/CFS for more than a decade. In 2010, he developed a standard questionnaire (The DePaul Symptom Questionnaire, DSQ) to assess core symptoms of ME/CFS, with the aim of ensuring that symptoms are assessed in a consistent way across settings to aid in diagnosis.

This questionnaire has now been refined (Jason et al, American Journal of Biochemistry and Biotechnology) and is being made available to other research groups for operational testing on existing ME/CFS cohorts. Importantly, the DSQ now comes in a format which scores symptoms and SF36 data, and produces a “diagnosis” based on several of the more common definitions of ME, CFS and ME/CFS. If this instrument is found to be sufficiently sensitive, it could greatly assist patient diagnosis, saving time (as it can be completed in the patient’s home and brought to the clinic for scoring) and improving confidence in the diagnosis.

In the course of the ME Research UK-funded patient cohort study at Newcastle University, the researchers have collected a large volume of clinical, autonomic and symptom data, and they have available full data sets from almost 200 patients who have attended the Newcastle ME/CFS Service and been referred to their research programme. Each of these patients has been assessed on the basis of the Fukuda 1994 CFS and the Canadian 2003 ME/CFS definitions as part of their clinical examinations, but through the timely development of the DSQ an opportunity has arisen to compare the clinical diagnoses of patients in the Newcastle ME Research UK cohort with those derived from the more structured DSQ instrument. The results obtained will also be shared with Prof. Jason’s group in Chicago, adding to the data on the usefulness of the DSQ which he hopes to acquire from research groups around the world in different populations of patients. Considering the importance of the ME Research UK cohort and its well-characterised nature, the results could throw valuable light on diagnostic categories and on the utility of the DSQ in practice.

Source: ME Research 


previous article
  Rating 2 (1 votes) next article




DISCUSS THIS ARTICLE   (0 existing comments) Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Your Next Order

Featured Products
Ubiquinol CoQ-10 Ubiquinol CoQ-10
Reduced, Active Form of CoQ10
Phosphatidyl Serine Phosphatidyl Serine
Sharpen memory and mental acuity
Fatigued to Fantastic!™ Energy Revitalization System - Berry Splash Fatigued to Fantastic!™ Energy Revitalization System - Berry Splash
Vitality, Health and Lasting Energy
B-12 Extreme™ B-12 Extreme™
The Most Potent Vitamin B-12 on Earth
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid

Most Viewed Articles
What's the Hidden Cause Behind YOUR Fibromyalgia Flares? [more]

Pridgen Reports Fibromyalgia Antiviral Trial Results “Very Positive”: Predicts New Approach Will Be ... [more]

Massage Therapy Studies for Fibromyalgia Reviewed [more]

How to Limit or Minimize Your Fibromyalgia Flare [more]

Breaking News: FDA’s Sneak Attempt to Ban Another B Vitamin [more]

Mitochondrial Dysfunction, Post-Exertional Malaise and CFS/ME [more]

The Devil Is In The Details – A Herpes Simplex Virus Inquiry For Fibromyalgia and Chronic Fatigue Sy... [more]

Sensory Overload: Sources and Strategies [more]

Sympathetic Nervous System Dysfunction in FIbromyalgia and Overlapping Conditions [more]

Review of Nutritional Supplements Used for ME/CFS and FM [more]


FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing